Brenda Waning

Brenda Waning is a globally-recognized expert in pharmaceutical policy and access to medicines, currently serving as Chief of the Stop TB Global Drug Facility. After commencing her career as an Assistant Professor of Pharmacy Practice at the Massachusetts College of Pharmacy and Allied Health Sciences in Boston, Brenda Waning went on to dedicate over 25 years to improving access to essential medicines globally. During her tenure at the College, she taught various courses and authored sections for the seminal publication, Pharmacoepidemiology: Principles and Practice, detailing the scientific study of medication use and effects in large populations. Her academic contributions included significant research collaboration with institutions such as the Boston University School of Medicine and the Boston University School of Public Health in 2011, establishing her expertise in pharmaceutical policy and public health.

Brenda’s extensive experience spans academic, donor, and implementer roles, consistently focusing on the critical intersection of pharmaceutical policy, market shaping, and equitable access to vital medications worldwide. This comprehensive background has positioned her as a distinguished leader in international public health, adept at addressing global challenges related to drug accessibility. Her professional journey includes instrumental work with the Stop TB Partnership, where she spearheaded market-shaping initiatives and developed crucial procurement strategies for tuberculosis products, enhancing their availability in underserved regions. Currently, Brenda serves as the Chief of the Stop TB Global Drug Facility, a pivotal UN-hosted enterprise.

Her work at the Stop TB Global Drug Facility and her extensive career demonstrate a profound impact on global health, reinforcing her status as a leading authority in ensuring equitable access to life-saving medications worldwide.